Shanghai Junshi Biosciences' Unit Gets Marketing Approval for Cancer Drug by UK Regulator

MT Newswires Live11-18

Shanghai Junshi Biosciences (SHA:688180, HKG:1877) unit TopAlliance Biosciences has received marketing authorization and approval by UK Medicines and Healthcare products Regulatory Agency for its drug toripalimab for the treatment of two indications, a Nov. 15 bourse filing said.

The drug has been approved in combination with cisplatin and gemcitabine to treat adults with nasopharyngeal carcinoma, and in combination with cisplatin and paclitaxel for the treatment of adults with oesophageal squamous cell carcinoma.

Toripalimab has become the first and only drug to treat nasopharyngeal carcinoma and the only first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in the UK.

Shares of the pharmaceutical company were up nearly 2% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484614428?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 15:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484614428","market":"sg","top_or_hot":-1,"title":"Shanghai Junshi Biosciences' Unit Gets Marketing Approval for Cancer Drug by UK Regulator","media":"MT Newswires Live","content":"<html><body><p> Shanghai Junshi Biosciences (SHA:688180, HKG:1877) unit TopAlliance Biosciences has received marketing authorization and approval by UK Medicines and Healthcare products Regulatory Agency for its drug toripalimab for the treatment of two indications, a Nov. 15 bourse filing said. </p><p>The drug has been approved in combination with cisplatin and gemcitabine to treat adults with nasopharyngeal carcinoma, and in combination with cisplatin and paclitaxel for the treatment of adults with oesophageal squamous cell carcinoma.</p><p>Toripalimab has become the first and only drug to treat nasopharyngeal carcinoma and the only first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in the UK.</p><p>Shares of the pharmaceutical company were up nearly 2% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Junshi Biosciences' Unit Gets Marketing Approval for Cancer Drug by UK Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Junshi Biosciences' Unit Gets Marketing Approval for Cancer Drug by UK Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 15:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Junshi Biosciences (SHA:688180, HKG:1877) unit TopAlliance Biosciences has received marketing authorization and approval by UK Medicines and Healthcare products Regulatory Agency for its drug...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688180","symbol_name":"君实生物","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484614428","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484614428","pubTimestamp":1731916146,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Junshi Biosciences (SHA:688180, HKG:1877) unit TopAlliance Biosciences has received marketing authorization and approval by UK Medicines and Healthcare products Regulatory Agency for its drug","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","BK0239":"医药制造","BK1161":"生物科技","BK1515":"抗疫概念","01877":"君实生物","BK1583":"高瓴概念"},"translate_title":"上海君实生物旗下癌症药物获得英国监管机构上市批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"01877":0.9},"content_text":"Shanghai Junshi Biosciences (SHA:688180, HKG:1877) unit TopAlliance Biosciences has received marketing authorization and approval by UK Medicines and Healthcare products Regulatory Agency for its drug toripalimab for the treatment of two indications, a Nov. 15 bourse filing said. The drug has been approved in combination with cisplatin and gemcitabine to treat adults with nasopharyngeal carcinoma, and in combination with cisplatin and paclitaxel for the treatment of adults with oesophageal squamous cell carcinoma.Toripalimab has become the first and only drug to treat nasopharyngeal carcinoma and the only first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in the UK.Shares of the pharmaceutical company were up nearly 2% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484614428"}